Tonix Pharmaceuticals to Present at March Investor Conferences Amid Key Product Developments

Tonix Pharmaceuticals Holding Corp. announced that its management team will participate in two upcoming investor conferences in March 2026. Seth Lederman, M.D., president and chief executive officer, will deliver a company presentation at the TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026, from 11:10 a.m. to 11:40 a.m. ET at the Boston Marriott Copley Place in Boston. In addition, management will participate in one-on-one meetings at the Barclays 28th Annual Healthcare Conference, scheduled for March 10-12, 2026, at the Loews Miami South Beach Hotel in Miami Beach.

These investor presentations come at a significant time for Tonix Pharmaceuticals, a fully-integrated, commercial-stage biotechnology company focused on central nervous system and immunology treatments in areas of high unmet medical need. The company's recently approved flagship medicine, TONMYA, represents the first new treatment for fibromyalgia in more than 15 years, marking a substantial advancement in a therapeutic area that has seen limited innovation. This development matters because fibromyalgia affects millions of patients worldwide who have had few effective treatment options, making TONMYA's approval potentially transformative for patient care and quality of life.

Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. The company is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. This expansion into additional indications is important because it could significantly broaden the therapeutic applications of TONMYA, potentially addressing multiple serious mental health conditions that affect large patient populations. The company's CNS portfolio also includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease with limited treatment options.

Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These developments are crucial because they represent innovative approaches to preventing serious infectious diseases and improving transplant outcomes, areas where current medical solutions remain inadequate. The company's participation in these investor conferences provides an opportunity to communicate these developments to the investment community, potentially influencing future research funding and strategic partnerships.

The implications of these investor presentations extend beyond immediate financial considerations. As detailed in the company's newsroom available at https://ibn.fm/TNXP, Tonix's progress in multiple therapeutic areas demonstrates the company's strategic positioning in high-need medical markets. The convergence of commercial-stage products with promising pipeline candidates creates a diversified portfolio that could drive long-term growth while addressing significant patient needs. For investors and stakeholders, these conferences offer insight into how Tonix plans to leverage its scientific advancements to create value and improve patient outcomes across multiple disease areas.